Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Melanoma 25Uveal Melanoma 5Skin Neoplasms 3Neoplasms 3Eye Neoplasms 2Breast Neoplasms 2Urologic Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm Metastasis 1Muscle Neoplasms 1Lung Neoplasms 1Histiocytoma, Malignant Fibrous 1Genetic Diseases, Inborn 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Bone Neoplasms 1

Interventions

pembrolizumab 1niraparib 1montanide ISA 51 1flt3 ligand protein 1atezolizumab 1MART-1 Antigen 1Immunoglobulins, Intravenous 1Gemcitabine 1GSK-3326595 1Etoposide 1Cyclophosphamide 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × montanide ISA 51 × Dermatologic × Clear all
NCT00019396 2024-03-04

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms, Skin Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡